A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer.
Chu MatsudaToshihiro KudoYoshihiro MorimotoYoshinori KagawaMitsuyoshi TeiYoshihito IdeNorikatsu MiyoshiHidekazu TakahashiMamoru UemuraIchiro TakemasaTaroh SatohTsunekazu MizushimaKohei MurataYuichiro DokiHidetoshi Eguchinull nullPublished in: Annals of gastroenterological surgery (2022)
XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3-year DFS, and measures of safety met current standards.